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Abstract Very recently we have proposed [Hemrika et al. 
(1997) Proc. Natl. Acad. Sei. USA 94, 2145-2149] that the 
active site of the vanadate-containing chloroperoxidase from the 
fungus Cuvvularia inaequatis, of which the tertiary structure is 
known, is structurally very similar to that of the membrane-
bound mammalian glucose-6-phosphatases for which no structur-
al data are available. The proposed active site of glucose-6-
phosphatase, however, is incompatible with the six transmem-
brane-helix topology model that is currently used. Here we 
present a new topology model for glucose-6-phosphatase which is 
in agreement with all available data. 
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1. Introduction 
Glucose-6-phosphatase (G-6-Pase) is an enzyme tightly as-
sociated with the endoplasmatic reticulum (ER) and nuclear 
membranes of liver and kidney cells [1]. G-6-Pase catalyzes 
the last step in both gluconeogenesis and glycogenolysis and 
as such it is the key enzyme in glucose homeostasis [1]. Gly-
cogen storage disease type 1 (von Gierke disease) is an auto-
somal recessive disorder — with an incidence of about 
1:100 000 in humans — that is the consequence of the absence 
of G-6-Pase activity. This disorder is characterized by severe 
clinical manifestations such as hypoglycemia, growth retarda-
tion, hepatomegaly, kidney enlargement, hyperlipidemia, hy-
peruriceamia and lactic acidosis [2,3]. Without dietary treat-
ment patients suffering from this disease die early, usually in 
their teens, of liver and kidney complications [4]. 
Research on this disease has received an important impetus 
by the recent isolation and sequencing of the genes encoding 
this enzyme in human, rat and mouse [5-7]. The deduced 
amino acid sequences show that these proteins are highly 
( > 90%) similar. Analysis of their hydropathy profiles indi-
cated the presence of at least six putative membrane-spanning 
regions and accordingly a topology model for G-6-Pase was 
proposed in which six membrane spanning helices are incor-
porated [5] (see also Fig. 2A). This model has been used as the 
template in several structure-function relation studies on G-6-
Pase [8,9]. Mutations, that abolished or greatly reduced G-6-
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Pase activity, in the G-6-Pase gene of von Gierke patients 
have also been identified [4,8,9]. Arg83 of G-6-Pase turned 
out to be a very important residue for enzyme activity. It 
was demonstrated that an Arg83 to Cys mutation completely 
abolishes G-6-Pase activity and the structural requirements of 
this codon were examined by replacing Arg83 with the amino 
acids Glu, Lys, Met, Leu, Asn, Gin, Ser and Thr, respectively 
[9]. None of these replacements resulted in restoration of G-6-
Pase activity. The authors [9] therefore postulated that Arg83 
of G-6-Pase is involved in positioning of phosphate. Since it is 
known that a phosphohistidine intermediate is formed during 
G-6-Pase catalysis [10,11] the authors [9] subsequently mu-
tated the four histidines that, according to the six transmem-
brane-helix topology model, reside on the same side of the 
ER membrane as Arg83. Only His119 turned out to be abso-
lutely required for G-6-Pase activity and therefore it was sug-
gested that His119 is the phosphate acceptor during G-6-Pase 
catalysis. Very recently, however, based on several lines of 
evidence, we have proposed that this may be incorrect [12]. 
2. Evidence for a new membrane topology 
Vanadate-containing haloperoxidases catalyze the peroxida-
tion of a halide to the corresponding hypohalous acid. The 
recent determination of the primary [13] and tertiary [14] 
structure of one such enzyme, the vanadate-containing chloro-
peroxidase (V-CPO) from the fungus Curvularia inaequalis 
revealed that the amino acids contributing to the active site 
of this enzyme are conserved in the bromoperoxidase (V-BPO) 
from the seaweed Ascophyllum nodosum [14] and surprisingly, 
also in the G-6-Pases and at least two other families of acid 
phosphatases that were previously considered unrelated [12]. 
It should be noted that this conservation is only restricted to 
the domains providing these residues, while overall identity is 
very low. 
Vanadate and phosphate are structurally very similar and 
many acid phosphatases — including G-6-Pase — are inhibited 
by vanadate [15]. Further, vanadate-containing haloperoxi-
dases rapidly loose their activity in phosphate-containing buf-
fers and reconstitution of apo-BPO by vanadate is inhibited in 
the presence of phosphate [16]. 
351-EKWEFEFWRPLSGVRDD 395-PFPAYPSGHATFG 488-SRIFLGVHWRFDAAA 
7 4-FKWILFGQRPYWWVLDT 110-TGPGSPSGHTIFÄ 168-SRIYLAAHFPHQWA 
Fig. 1. Alignment of the active site domains of the V-CPO from C. 
inaequalis [14] to the proposed active site domains of G-6-Pase of 
human, rat and mouse (which are identical in these regions) [5-7]. 
Residues directly involved in the V-CPO active site are given in 
bold face. Identical residues are indicated with an asterisk. 
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Fig. 2. Membrane topology models for G-6-Pase. A: Current six transmembrane-helix topology model (adapted from [9]). B: Newly proposed 
nine transmembrane-helix topology model. Residues predicted to be on the membrane interface are depicted as open ovals. Putative G-6-Pase 
active site residues are depicted as closed ovals. 
We have also established that apo-CPO from C. inaequalis 
is able to hydrolyze the commonly used phosphatase substrate 
/7-nitrophenyl phosphate (p-NPP) and thus can function as a 
phosphatase [12]. We therefore proposed that the residues 
involved in the binding of vanadate and/or peroxidative cat-
alysis in holo-CPO are also involved in the binding of phos-
phate and subsequent p-NPP hydrolysis in apo-CPO and as a 
consequence that the active site of the vanadium-containing 
haloperoxidases is structurally very similar to that of the 
aligned acid phosphatases [12]. 
Fig. 1 shows the alignment of the residues of the active site 
of the V-CPO to the proposed phosphate binding site of the 
G-6-Pases. It can be seen that Arg83 of G-6-Pase aligns to 
Arg360 of V-CPO, a residue donating hydrogen bonds to va-
nadate, indeed making Arg83 a likely candidate for position-
ing phosphate in G-6-Pase. His119 of G-6-Pase, however, does 
not align to His490 of V-CPO, the residue covalently binding 
vanadate, but to His404, a proposed acid-base group in catal-
ysis [14]. The histidine of G-6-Pase aligning to His490 of V-
CPO is His176, but according to the six transmembrane-helix 
topology model, this residue is situated at the opposite site of 
the membrane as Arg83 and His119 (see Fig. 2A). We sug-
gested therefore, that His176 resides on the same side of the 
ER membrane as Arg83 and His119 and thus that the proposed 
membrane topology [5,6] is in need of revaluation [12]. 
Fig. 2B shows our new model for the membrane topology 
of G-6-Pase which is based on the presented evidence concern-
ing the nature of the G-6-Pase active site and the results of 
two new algorithms for the prediction of membrane-spanning 
domains [17-20]. These algorithms independently predict nine 
transmembrane helices in G-6-Pase as opposed to the previous 
topology model [5,6]. With this newly predicted topology all 
residues aligning to the active site residues of V-CPO are 
situated on the same — luminal — side of the ER-membrane 
(compare Fig. 2A and B). We propose therefore that helices 
II, III, IV and V are in close contact and provide the phos-
phate binding and glucose-6-phosphate hydrolysis site of G-6-
Pase. 
In our model His176 of G-6-Pase is the nucleophile forming 
the phosphohistidine enzyme-substrate intermediate. The 
phosphate moiety is positioned by interaction of the nega-
tively charged oxygens with the positively charged Lys76, 
Arg83 and Arg170, while analogous to V-CPO Ser117 and 
Gly118 may also donate hydrogen bonds. His119 may provide 
the proton needed to liberate the glucose moiety. 
Thus, the common architecture of the active sites of the 
vanadate containing haloperoxidases and the aligned acid 
phosphatases [12], for which at present no structural data 
are available, has important implications for both research 
in the acid phosphatase and in the peroxidase field. With a 
new topology model for G-6-Pase and with the designation of 
the putative residues involved in the binding and the hydrol-
ysis of glucose-6-phosphate the first of these implications may 
have become evident. 
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